Related Experiment Video
Updated: Sep 20, 2025
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
Published on: August 1, 2025
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with
Abdullah Sonsuz1, Selma Bozcan1, İbrahim Hatemi1
1Department of Gastroenterology, İstanbul University-Cerrahpaşa Cerrahpaşa School of Medicine, İstanbul, Turkey.
Insights
Direct-acting antivirals effectively treat Hepatitis C in patients with inherited bleeding disorders. This combination therapy achieved a sustained virologic response in all participants, demonstrating its efficacy and safety for this vulnerable population.
Area of Science:
- Hepatology
- Hematology
- Virology
Background:
- Hepatitis C is a significant cause of mortality in individuals with inherited bleeding disorders.
- Direct-acting antiviral (DAA) drugs offer an effective treatment for Hepatitis C.
- Patients with inherited bleeding disorders represent a unique population requiring specific treatment considerations.
Purpose of the Study:
- To evaluate the efficacy and safety of a specific direct-acting antiviral combination (ombitasvir + paritaprevir/ritonavir and dasabuvir) in patients with inherited bleeding disorders and Hepatitis C genotype 1 infection.
- To assess the sustained virologic response rates and identify any adverse events in this patient cohort.
Main Methods:
- A retrospective study involving 15 adult patients with inherited bleeding disorders (hemophilia A, hemophilia B, von Willebrand disease) and Hepatitis C genotype 1.
- Treatment involved the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir, with or without ribavirin.
- Efficacy was assessed by Hepatitis C virus RNA negativity at week 4 and end of treatment; safety was monitored for adverse events.
Main Results:
- All 15 patients achieved a sustained virologic response, with undetectable Hepatitis C virus RNA at week 4 and end of treatment.
- The study included patients with both genotype 1a (5 patients) and 1b (10 patients) Hepatitis C.
- Three patients experienced serious adverse events: intramuscular bleeding, gastrointestinal bleeding, and pneumonia.
Conclusions:
- The combination of ombitasvir + paritaprevir/ritonavir and dasabuvir is an effective treatment for genotype 1 Hepatitis C in patients with coagulation disorders.
- The observed side effect profile and tolerance are comparable to other available treatment options.
- This DAA regimen provides a valuable therapeutic option for managing Hepatitis C in individuals with inherited bleeding disorders.
Background:
Hepatitis C is one of the leading causes of death in patients with inherited bleeding disorders. Currently, direct-acting antiviral drugs used for the treatment of hepatitis C have become an effective and a reliable option for people with inherited bleeding disorders. The aim of this study is to report the efficacy and safety of ombitasvir + paritaprevir/ritonavir and dasabuvir combination in the treatment of hepatitis C in patients with inherited bleeding disorders.
Methods:
In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1.
Results:
Five patients had genotype 1a and 10 patients had genotype 1b chronic hepatitis C. One patient had Child A cirrhosis, 14 patients had chronic hepatitis C without cirrhosis. Hepatitis C virus ribonucleic acid was negative in all patients at week 4 and at the end of the treatment. Sustained virologic response was obtained in all patients. Serious side effects were detected in 3 patients, which were intra- muscular bleeding, erosive gastritis-related gastrointestinal bleeding, and pneumonia.
Conclusion:
Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders. Tolerance and side effects are similar to other treatment options.
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:15Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...